scholarly journals Activity of the p110-α subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport

2008 ◽  
Vol 295 (3) ◽  
pp. F843-F850 ◽  
Author(s):  
Jian Wang ◽  
Zachary A. Knight ◽  
Dorothea Fiedler ◽  
Olusegun Williams ◽  
Kevan M. Shokat ◽  
...  

The pathways implicated in the control of epithelial Na+ channel (ENaC)-dependent Na+ transport in renal collecting duct cells share substantial parallels with those implicated in insulin-regulated glucose metabolism. Notably, both are inhibited by wortmannin and LY294002 and signal through phosphatidylinositol-3-kinase (PI3K)-dependent kinases SGK1 and Akt. The inhibitor pattern is thought to reflect dependence on PI3K activity since wortmannin and LY294002 are both effective inhibitors of this kinase. However, these inhibitors block a variety of kinases from different families and lack specificity within the PI3K family. To begin to dissect more precisely the pathways required for signaling and for control of Na+ transport in renal collecting duct cells, we have examined the effect of a set of PI3K inhibitors, which selectively block distinct subsets of PI3K catalytic subunit isoforms. We have found that ENaC-dependent Na+ transport was blocked by inhibitors of the p110-α isoform of PI3K, but not by inhibitors of p110-β, -γ, or -δ. Inhibitors that block Na+ current also blocked SGK1 and Akt phosphorylation. In contrast to insulin-stimulated glucose uptake in muscle cells, p110-β inhibition did not enhance sensitivity to p110-α inhibition. These data support the conclusion that ENaC-dependent Na+ current is controlled exclusively by p110-α, the same isoform that is the principal mediator of insulin effects on glucose metabolism, and lacks any dependence on p110-β. These findings further underscore the extent to which Na+ and glucose regulation are intertwined and provide additional insight into the interconnections between diabetes and hypertension.

2001 ◽  
Vol 536 (3) ◽  
pp. 769-783 ◽  
Author(s):  
J. A. Sayer ◽  
G. S. Stewart ◽  
S. H. Boese ◽  
M. A. Gray ◽  
S. H. S. Pearce ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
pp. 183
Author(s):  
Annarita Di Mise ◽  
Maria Venneri ◽  
Marianna Ranieri ◽  
Mariangela Centrone ◽  
Lorenzo Pellegrini ◽  
...  

Vasopressin V2 receptor (V2R) antagonists (vaptans) are a new generation of diuretics. Compared with classical diuretics, vaptans promote the excretion of retained body water in disorders in which plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these conditions, an aquaretic drug would be preferable over a conventional diuretic. The clinical efficacy of vaptans is in principle due to impaired vasopressin-regulated water reabsorption via the water channel aquaporin-2 (AQP2). Here, the effect of lixivaptan—a novel selective V2R antagonist—on the vasopressin-cAMP/PKA signaling cascade was investigated in mouse renal collecting duct cells expressing AQP2 (MCD4) and the human V2R. Compared to tolvaptan—a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia—lixivaptan has been predicted to be less likely to cause liver injury. In MCD4 cells, clinically relevant concentrations of lixivaptan (100 nM for 1 h) prevented dDAVP-induced increase of cytosolic cAMP levels and AQP2 phosphorylation at ser-256. Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention.


1986 ◽  
Vol 33 (2) ◽  
pp. 156-167 ◽  
Author(s):  
Will W. Minuth ◽  
Peter Gilbert ◽  
Günter Lauer ◽  
Klaus Aktories ◽  
Peter Gross

2009 ◽  
Vol 11 (4) ◽  
pp. 616-628 ◽  
Author(s):  
Christophe Pichon ◽  
Céline Héchard ◽  
Laurence du Merle ◽  
Christelle Chaudray ◽  
Isabelle Bonne ◽  
...  

Life Sciences ◽  
2014 ◽  
Vol 118 (2) ◽  
pp. 195-199 ◽  
Author(s):  
Mollie E. Jacobs ◽  
Lauren A. Jeffers ◽  
Amanda K. Welch ◽  
Charles S. Wingo ◽  
Brian D. Cain

Sign in / Sign up

Export Citation Format

Share Document